Long Covid Symptoms Improve Less for Multi-System Patients
A three-year U.S. study of 1,019 adults found smell or taste-dominated symptoms improved far more often than multi-system symptoms.
Updated on Nov. 3, 2026 in COVID-19
A study of 1,019 U.S. adults with probable long Covid-19 found that about half experienced sustained symptom improvement over three years, with roughly a quarter reaching complete symptom remission. The study was published November 2 in Annals of Internal Medicine as part of the NIH-funded Recover initiative.
Why it matters
The findings show that long Covid outcomes differ sharply by symptom type, with patients who have multi-system symptoms recovering far less often. Because there is no approved treatment for long Covid-19, these differences help clarify which patients may face prolonged illness.
The study tracked 1,019 adults, and about 60% of those with smell or taste-dominated long Covid improved by three years compared with less than 19% of those with multi-system symptoms. The data do not explain the biological reasons for the gap or identify interventions that could narrow it.
The players
National Institutes of Health (NIH)
The NIH is the primary U.S. federal agency for biomedical and health research, and it funds the Recover initiative that supported this long Covid study.
Annals of Internal Medicine
Annals of Internal Medicine is a peer-reviewed medical journal published by the American College of Physicians that publishes clinical research and reviews.
The details
Researchers followed participants who were considered improved when their symptom score stayed below the likely long Covid-19 threshold at two successive visits. Symptoms tracked included fatigue, brain fog, dizziness, palpitations, shortness of breath, and changes in smell or taste, with the scoring system giving substantial weight to loss of smell or taste and chronic cough.
Timeline
- November 2, 2026: Study published in Annals of Internal Medicine.
- Within three years of infection: Tracking period for symptom improvement outcomes.
Health Landscape
This study is part of the NIH-funded Recover initiative, which has been the main U.S. federal research effort on long Covid since the pandemic. The three-year outcome data add longer-term evidence to a field where no approved treatment for long Covid-19 currently exists.
Patients whose long Covid involves multi-system symptoms may face a lower chance of improvement within three years, which could shape expectations for recovery. Because no approved treatment exists, people with persistent symptoms should discuss their symptom pattern and options with a clinician.
The takeaway
Long Covid recovery varies by symptom type, and patients with multi-system symptoms are less likely to see sustained improvement over three years. Tracking symptom patterns over time may help clinicians set realistic expectations while research into treatments continues.
Further reading
Explore more COVID-19 coverage for context on long-term symptom research.
